- Despite a recent 35% decline in stock, Novo Nordisk (NVO, Financial) anticipates significant revenue growth, driven by its market-leading drugs.
- Analysts forecast a potential 76.65% upside in the stock, based on a one-year average target price of $103.04.
- GuruFocus estimates a substantial 168.97% upside potential, with a GF Value of $156.89 for the coming year.
Novo Nordisk (NVO), a leader in diabetes and obesity treatments, has experienced a challenging year with its stock value decreasing by nearly 35%. This decline has been primarily attributed to U.S. tariff threats on pharmaceutical imports. However, Novo Nordisk remains optimistic, projecting a robust revenue increase between 16% and 24% by 2025, bolstered by its innovative and market-leading therapies.
Wall Street Analysts Forecast
According to projections from nine analysts, the average one-year price target for Novo Nordisk AS (NVO, Financial) is $103.04. This forecast includes a high target estimate of $159.63 and a low of $63.85. The average target suggests a potential upside of 76.65% from the current trading price of $58.33. For more detailed data, investors can visit the Novo Nordisk AS (NVO) Forecast page.
The consensus from 15 brokerage firms indicates that Novo Nordisk AS (NVO, Financial) holds an average brokerage recommendation of 2.3, placing it in the "Outperform" category. This rating is part of a scale from 1 to 5, where 1 represents a Strong Buy and 5 a Sell.
GuruFocus GF Value Estimation
GuruFocus estimates the GF Value of Novo Nordisk AS (NVO, Financial) at $156.89 in one year, indicating a possible upside of 168.97% from its current price of $58.33. The GF Value is a sophisticated valuation metric that reflects the fair value based on the stock's historical trading multiples, past business growth, and future performance forecasts. Additional detailed insights can be accessed on the Novo Nordisk AS (NVO) Summary page.
